Global Cancer Supportive Care Therapeutics Market Opportunities, Biosimilars in the Chemotherapy & Industry Review to 2022
Latest niche market “Global Cancer Supportive Care Therapeutics Market to 2022-Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets” by Orbis Research
Dallas, United States – May 1, 2017 /MarketersMedia/ —
The cancer supportive care product market consists of drugs intended to prevent or treat the symptoms of cancer, and reduce the side effects of cancer treatments. Instead of extending a patient’s life expectancy, the emphasis is on improving overall quality of life. The key indications covered in this report are cancer pain, oral mucositis, chemotherapy-induced neutropenia (CIN), chemotherapy-induced anemia (CIA), chemotherapy-induced nausea and vomiting (CINV) and bone metastasis. These indications are not only distressing for patients, but can also lead to treatment cessation, which in turn increases patient mortality. As the number of people being diagnosed with cancer grows and access to effective treatment that allows patients to survive longer increases, demand for safe and effective cancer supportive care drugs will rise.
Buy a report @ http://www.orbisresearch.com/contact/purchase/275013.
Reasons to buy
This report will allow you to –
– Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report
– Understand the current treatment landscape, with profiles of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
– Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
– Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patents expirations will influence market value.
– Identify the leading companies in the market, in terms of market share and growth. Company analysis illustrates how dependent the key companies in the market are on revenue derived from cancer supportive care products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
– Identify commercial opportunities in the cancer supportive care deals landscape by analyzing trends in licensing and co-development deals.
Check the DISCOUNT @ http://www.orbisresearch.com/contacts/discount/275013.
Scope
The cancer supportive care market already contains some commercially successful products.
– Which classes of drug dominate the market?
– Which indication is the most commercially successful?
– How will commercially successful drugs perform over the forecast period?
The cancer supportive care pipeline is relatively small, but there is significant diversity in terms of molecule types and targets.
– Which molecular targets appear most frequently in the pipeline?
– What are the commercial prospects for the most promising late-stage pipeline products?
The cancer supportive care market is forecast to grow from $11.7 billion in 2015 to $12.4 billion in 2022, at a compound annual growth rate of 0.9%.
– Which products are forecast to drive growth?
– Will generic and biosimilar competition have a significant impact on the market over the forecast period?
The company landscape is becoming increasingly competitive.
– What are the leading companies in terms of market share?
– Which companies are forecast to experience the greatest growth in market share?
– What are the drivers of growth for key companies in the market?
– How dependent are the key companies on this disease cluster for revenue?
The level of unmet need within the cancer supportive care therapy area varies between indications. CIN and CINV both already have treatment regimens that can significantly decrease the incidence rate. However, the level of unmet need for CIA, cancer pain, oral mucositis and bone metastasis is high, with treatment focusing heavily on alleviating the symptoms instead of treating the underlying cause.
There are 245 products in active development in the cancer supportive care pipeline, but this includes products in development for smaller and less commercially significant indications. There are 169 products in active development for the key indication examined in this report, giving an average of 28 products per indication, the majority of which are at an early stage of development.
Read the more detail of this report @ http://www.orbisresearch.com/reports/index/global-cancer-supportive-care-therapeutics-market-to-2022-patent-expirations-create-opportunities-for-biosimilars-in-the-chemotherapy-induced-anemia-and-neutropenia-markets.
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Name: Hector Costello
Email: sales@orbisresearch.com
Organization: Orbis Research
Address: 144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +912064101019
For more information, please visit http://www.orbisresearch.com/reports/index/global-cancer-supportive-care-therapeutics-market-to-2022-patent-expirations-create-opportunities-for-biosimilars-in-the-chemotherapy-induced-anemia-and-neutropenia-markets
Source: MarketersMedia
Release ID: 192383
Copyright © 1999-2013 SproutNews.com
